BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
BioAtla, Inc. (BCAB)
Company Research
Source: Yahoo! Finance
Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient derived pancreatic cancer model No clinical and histopathologic signs of toxicities in non-human primates with conditionally active tetravalent B7-H3 x CD3 T-cell engager (BA3142) SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024. Presentation Details: Poster Title: Using a novel NextGen linker system to generate a Conditionally Active Biologic (CAB) anti-Nectin4-ADC demonstrates improved efficacy in pancreat
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla, Inc. (NASDAQ: BCAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
- BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswire
- BioAtla to Participate in the Citizens JMP Life Sciences ConferenceGlobeNewswire
- BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024GlobeNewswire
BCAB
Earnings
- 5/14/24 - Beat
BCAB
Sec Filings
- 5/17/24 - Form 8-K
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- BCAB's page on the SEC website